Healthcare / Medical DevicesTaipei Exchange
$7.01
+0.01 (+0.14%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-41.7M · quality 47.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
17/100
F
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$285M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-203.4%
↓Gross Margin
62.9%
↑Debt/Equity
1.60
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-36.6%
FCF CAGR
—
FCF margin
-138.7%
FCF / Net income
0.79x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $26.9M · net income $-47.0M · FCF $-37.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $26.9M | $26.9M | $19.5M | $20.9M | $105.2M |
| Net Income | $-47.0M | $-47.0M | $-46.8M | $-63.2M | $-4.9M |
| EBITDA | $-39.6M | $-39.6M | $-39.3M | $-56.8M | $2.4M |
| EPS | — | — | -2.05 | -2.69 | -0.21 |
| Gross Margin | 62.9% | 62.9% | 30.8% | 7.7% | 59.5% |
| Operating Margin | -170.1% | -170.1% | -236.8% | -301.8% | -5.0% |
| Net Margin | -174.7% | -174.7% | -240.5% | -302.5% | -4.6% |
| Balance Sheet | |||||
| Debt/Equity | 1.60 | 1.60 | 3.77 | 1.60 | 0.21 |
| Current Ratio | 1.59 | 1.59 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-37.3M | $-37.3M | $-41.7M | $-47.9M | $7.4M |
| Returns | |||||
| ROE | -203.4% | -203.4% | -465.7% | -193.1% | -6.1% |
| Valuation | |||||
| EV/EBITDA | — | — | — | — | 262.09 |
| P/B | 12.33 | 12.33 | 13.00 | 15.05 | 8.12 |
| Growth & Yield | |||||
| Revenue Growth | 38.1% | 38.1% | -6.8% | -80.2% | — |
| EPS Growth | — | — | 23.9% | -1180.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+11.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-2.05 → n/d
Residual
+11.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.